June 14, 2024

795-P: Balancing the Scales—The Effect of Tirzepatide on Lean Body Mass and Fat Mass

Key Points

Key points are not available for this paper at this time.

Abstract

Introduction Abbott. Other Relationship; Dexcom, Inc. Consultant; Bayer Inc. Other Relationship; Novo Nordisk, Eli Lilly and Company. Consultant; Boehringer-Ingelheim, AstraZeneca.

Bookmark

Cite This Study

BODENSTAB et al. (Fri,) studied this question.

synapsesocial.com/papers/68e64b41b6db6435875dc4dc https://doi.org/https://doi.org/10.2337/db24-795-p

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1EFFICACY OF TIRZEPATIDE ON WEIGHT LOSS, MUSCLE MASS AND CARDIOVASCULAR HEALTH IN THE ADULT POPULATION WITH DIABETES TYPE 2, OVERWEIGHT OR OBESITY: A SYSTEMATIC REVIEW2026
21676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide2026
31707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience2024
41660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience2024 · 2 citations
5238-OR: Effect of Baseline Antihyperglycemic Medications on Weight Reduction with Tirzepatide—SURMOUNT-2 Subgroup Analysis2024

Bookmark